Mustang Bio treatment of malignant glioma granted orphan designation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 01 2025
0mins
FDA Orphan Designation: Mustang Bio's treatment for malignant glioma has received orphan designation from the FDA, indicating it is intended for a rare disease.
Significance of Orphan Designation: This designation can provide various benefits, including incentives for the development of treatments for conditions affecting fewer than 200,000 patients in the U.S.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MBIO
About MBIO
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for cancers and autoimmune diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. It is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. It has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ford Unveils 2027 Bronco RTR SUV, Priced Between $51,475 and $80,000
- New Model Launch: Ford has announced the introduction of the 2027 Bronco RTR SUV, the eighth model in the Bronco lineup, designed to blend off-road and street performance, thereby enriching its product offerings.
- Powertrain Specs: The new Bronco RTR will feature a 2.3-liter turbocharged four-cylinder engine delivering 315 horsepower and 350 pound-feet of torque, which, while less powerful than the Bronco Raptor's 418 horsepower, still offers robust performance appealing to off-road enthusiasts.
- Market Positioning: Although Ford has not disclosed specific pricing, the Bronco RTR is expected to be priced between the $51,475 Bronco Heritage Edition and approximately $80,000 for the Bronco Raptor, positioning it as a more accessible performance model.
- Sales Timeline: The Bronco RTR will be available for order starting in October, with sales commencing in January 2027, further enhancing Ford's competitiveness in the SUV market.
Continue Reading
Ford Expands Bronco Lineup with New RTR Model Positioned Between $51,475 and $80,000
- New Model Launch: Ford has announced the introduction of the 2027 Bronco RTR SUV, the eighth model in the Bronco lineup, which combines off-road and street performance to attract a broader consumer base.
- Pricing Positioning: While Ford has not disclosed specific pricing, the Bronco RTR is expected to be positioned between the $51,475 Bronco Heritage Edition and the roughly $80,000 Bronco Raptor, making it a more accessible performance model.
- Powertrain Details: The Bronco RTR will feature a 2.3-liter turbocharged four-cylinder engine delivering 315 horsepower and 350 pound-feet of torque, which, although lower than the Raptor's 418 horsepower and 440 pound-feet, still offers robust performance.
- Market Strategy: The launch of this model aligns with Ford's strategy to leverage its well-known brands such as Bronco, Mustang, and F-150, aiming to meet the demand for affordable performance vehicles among off-road enthusiasts.
Continue Reading